Correspondence 0001104659-23-120165 from Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Date: Nov. 21, 2023 · CIK: 0001651407 · Accession: 0001104659-23-120165
AI Filing Summary & Sentiment
File numbers found in text: 333-275644
Letter
Re: Checkpoint Therapeutics, Inc.
November 21, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-275644
Ladies and Gentlemen:
Checkpoint Therapeutics, Inc. (the “Company”) hereby requests, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 4:00 p.m. EST on November 24, 2023, or as soon thereafter as practicable.
Please contact Matt Mamak of Alston & Bird LLP, the Company’s counsel, at (212) 210-1256, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Checkpoint Therapeutics, Inc.
By: /s/ James F. Oliviero
Name: James F. Oliviero
Title: Chief Executive Officer and President
Show Raw Text
CORRESP
1
filename1.htm
November 21, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Checkpoint Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-275644
Ladies and Gentlemen:
Checkpoint Therapeutics, Inc.
(the “Company”) hereby requests, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933,
as amended, that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective
at 4:00 p.m. EST on November 24, 2023, or as soon thereafter as practicable.
Please contact Matt Mamak
of Alston & Bird LLP, the Company’s counsel, at (212) 210-1256, as soon as the Registration Statement has been declared effective,
or if you have any other questions or concerns regarding this matter.
Checkpoint Therapeutics, Inc.
By:
/s/
James F. Oliviero
Name: James F. Oliviero
Title: Chief Executive Officer and President